Viatris

Viatris Inc. is a global healthcare company headquartered in Canonsburg, Pennsylvania. Formed in 2020 through the merger of Mylan and Pfizer's Upjohn business, Viatris operates in more than 165 countries and territories. The company's portfolio encompasses a wide range of products including generics, complex generics, biosimilars, and over-the-counter medications across various therapeutic areas. Viatris operates through four segments: Developed Markets, Greater China, JANZ (Japan, Australia, and New Zealand), and Emerging Markets. Its key product offerings include well-known brands such as Lipitor, Viagra, Xanax, and Celebrex, among others. The company's manufacturing capabilities span over 40 sites globally, producing oral solid doses, injectables, complex dosage forms, and active pharmaceutical ingredients. In 2021, Viatris reported revenues of USD 17.8 billion and employed approximately 37,000 people worldwide. The company has been actively reshaping its portfolio, divesting non-core assets to focus on strategic areas. In October 2023, Viatris announced the sale of its over-the-counter, women's healthcare, and active pharmaceutical ingredient businesses for a combined value of USD 3.6 billion. As part of its strategic transformation, Viatris is concentrating on expanding its ophthalmology franchise, aiming to achieve USD 1 billion in eye care sales by 2028.

Key customers and partnerships

Viatris serves a diverse customer base across multiple industries and geographies. In Australia, the company is one of the leading suppliers of medicines to the Pharmaceutical Benefits Scheme, with 43 out of the top 50 PBS products distributed by volume being Viatris medicines as of September 2022. The company's global reach is evident in its 2021 performance, where it sold more than 80 billion doses of medicine worldwide and reached approximately 90% of low- and lower-middle-income countries with about 7.7 billion doses of medicine. Viatris has established partnerships to enhance its product offerings and market presence. In February 2023, the company completed the acquisitions of Oyster Point Pharma and Famy Life Sciences to create its new Eye Care Division, expanding its portfolio in the ophthalmology sector. Additionally, Viatris has collaborated with educational partners to develop talent pipelines and foster skills in the next generation of professionals in the pharmaceutical industry.